Clinical trials: Brentuximab
Peripheral T Cell Lymphoma, Pediatric Hodgkin Lymphoma
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
The purpose of this survey is to examine the safety of adult patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) (excluding anaplastic large cell lymphoma (ALCL)) and pediatric patients with…
- Trial name
- NCT04213209
- Testing
- Brentuximab Vedotin (Genetical Recombination)
- Where
- Japan
- Volunteers
- 95 people
- Sponsor
- Takeda
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A).
- Conditions
- Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
- Trial name
- NCT01421667
- Testing
- brentuximab vedotin, rituximab
- Where
- 34 sites in United States, Canada
- Volunteers
- 176 people
- Sponsor
- Seagen Inc.
Hodgkin Lymphoma
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
This trial will study two treatment combinations for classical Hodgkin lymphoma (cHL). This trial will find out if these two treatment combinations work to treat cHL. It will also find out what side effects occur.
- Trial name
- NCT03646123
- Testing
- brentuximab vedotin, doxorubicin, vinblastine
- Where
- 76 sites in United States, Australia and 4 more
- Volunteers
- 255 people
- Sponsor
- Seagen Inc.
Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
This phase I/II trial studies the side effects and the best dose of brentuximab vedotin when given together with gemcitabine hydrochloride and to see how well they work in treating younger patients with Hodgkin lymphoma that has…
- Conditions
- Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Refractory Childhood Hodgkin Lymphoma
- Trial name
- NCT01780662
- Testing
- Brentuximab Vedotin, Gemcitabine Hydrochloride
- Where
- 116 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
This phase II trial studies how well ibrutinib and brentuximab vedotin work in treating patients with Hodgkin lymphoma that has returned (relapsed) or does not respond to treatment (refractory).
- Trial name
- NCT02744612
- Testing
- Brentuximab Vedotin, Ibrutinib
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- City of Hope Medical Center
Hodgkin Disease
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with…
- Trial name
- CheckMate 744 (NCT02927769)
- Testing
- Nivolumab, brentuximab vedotin, bendamustine
- Where
- 79 sites in United States, Canada and 9 more
- Volunteers
- 72 people
- Sponsor
- Bristol-Myers Squibb
Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with brentuximab vedotin (SGN-35) in patients who have previously participated in an brentuximab vedotin study.
- Conditions
- Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
- Trial name
- NCT00947856
- Testing
- brentuximab vedotin
- Where
- 17 sites in United States, France
- Volunteers
- 110 people
- Sponsor
- Seagen Inc.
Hodgkin Disease
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen…
- Trial name
- NCT02979522
- Testing
- Brentuximab vedotin, Doxorubicin, Vinblastine
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 59 people
- Sponsor
- Takeda
Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.
- Trial name
- NCT00866047
- Testing
- brentuximab vedotin
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 58 people
- Sponsor
- Seagen Inc.
Untreated CD30-Positive Hodgkin's Lymphoma
Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"
The purpose of this survey is to monitor and identify the occurrence of neutropenia and febrile neutropenia in untreated CD30-positive Hodgkin's lymphoma participants on concomitant brentuximab vedotin and doxorubicin…
- Trial name
- NCT03729609
- Testing
- Brentuximab vedotin (Genetical Recombination)
- Where
- Japan
- Volunteers
- 113 people
- Sponsor
- Takeda
Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
This pilot phase II trial studies how well giving brentuximab vedotin, combination chemotherapy, and radiation therapy works in treating younger patients with stage IIB, IIIB or IV Hodgkin lymphoma.
- Conditions
- Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
- Trial name
- NCT01920932
- Testing
- brentuximab vedotin, etoposide, prednisone
- Where
- 6 sites in United States
- Volunteers
- 77 people
- Sponsor
- St. Jude Children's Research Hospital
Relapsed or Refractory Hodgkin Lymphoma, Relapsed or Refractory Anaplastic Large-cell Lymphoma
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
The purpose of this study is to assess the safety and pharmacokinetics, and determine the pediatric maximum tolerated dose and/or or recommended phase 2 dose of brentuximab vedotin.
- Trial name
- NCT01492088
- Testing
- Brentuximab vedotin
- Where
- 18 sites in United States, France and 6 more
- Volunteers
- 36 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Non-Hodgkin's Disease
An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas
The purpose of this study is to determine whether Nivolumab, in combination with brentuximab vedotin, is safe and effective in patients with certain subtypes of non-Hodgkin's lymphomas with CD30 expression that have not responded…
- Trial name
- CheckMate 436 (NCT02581631)
- Testing
- Nivolumab, Brentuximab Vedotin
- Where
- 27 sites in United States, Canada and 4 more
- Volunteers
- 145 people
- Sponsor
- Bristol-Myers Squibb
Acute Lymphoid Leukemia, Acute Myeloid Leukemia
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.
- Conditions
- Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts, Solid Tumors
- Trial name
- NCT01461538
- Testing
- brentuximab vedotin
- Where
- 29 sites in United States
- Volunteers
- 84 people
- Sponsor
- Seagen Inc.
Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma
Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
The purpose of this study is to evaluate the safety of brentuximab vedotin (recombinant) for intravenous (IV) infusion (ADCETRIS IV Infusion 50 mg) in patients with relapsed/refractory CD30+ Hodgkin's lymphoma or anaplastic large…
- Trial name
- NCT02139592
- Testing
- Brentuximab vedotin (recombinant)
- Where
- Japan
- Volunteers
- 292 people
- Sponsor
- Takeda
Disease, Hodgkin
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.
- Trial name
- NCT00848926
- Testing
- brentuximab vedotin
- Where
- 27 sites in United States, Belgium and 3 more
- Volunteers
- 102 people
- Sponsor
- Seagen Inc.
Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
This partially randomized phase II trial studies how well brentuximab vedotin or crizotinib and combination chemotherapy works in treating patients with newly diagnosed stage II-IV anaplastic large cell lymphoma.
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
- Trial name
- NCT01979536
- Testing
- Brentuximab Vedotin, Crizotinib, Cyclophosphamide
- Where
- 154 sites in United States
- Volunteers
- 137 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin's Lymphoma
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is determine if 2 cycles of SGN-35 can be used instead of ICE prior to autologous stem cell transplant (ASCT) for relapsed and refractory HL.
- Trial name
- NCT01508312
- Testing
- brentuximab vedotin (SGN-35)
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
This phase II trial studies how well brentuximab vedotin and nivolumab work in treating patients with stage I-II classic Hodgkin lymphoma.
- Conditions
- Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma
- Trial name
- NCT03712202
- Testing
- Bleomycin, Brentuximab Vedotin, Dacarbazine
- Where
- 17 sites in United States
- Volunteers
- 159 people
- Sponsor
- City of Hope Medical Center
Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
This phase III trial studies brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating children and young adults with stage IIB with bulk, stage IIIB, IVA…
- Conditions
- Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma
- Trial name
- NCT02166463
- Testing
- Bleomycin Sulfate, Brentuximab Vedotin, Cyclophosphamide
- Where
- 199 sites in United States, Canada and 1 more
- Volunteers
- 600 people
- Sponsor
- National Cancer Institute (NCI)